- 专利标题： PD-L1 expressing hematopoietic stem cells and uses
-
申请号： US16685238申请日： 2019-11-15
-
公开(公告)号： US10751373B2公开(公告)日： 2020-08-25
- 发明人: Paolo Fiorina
- 申请人： The Children's Medical Center Corporation
- 申请人地址： US MA Boston
- 专利权人： The Children's Medical Center Corporation
- 当前专利权人： The Children's Medical Center Corporation
- 当前专利权人地址： US MA Boston
- 代理机构： Nixon Peabody LLP
- 代理商 David S. Resnick
- 主分类号： A61K35/28
- IPC分类号： A61K35/28 ; C07K16/28 ; C12N5/0789 ; A61P3/10 ; C07K14/705 ; A61K39/00
摘要：
Embodiments disclosed here provide engineered modified hematopoietic stem cells (HSCs), artificially prostaglandin E2 (PGE2)-stimulated HSCs, compositions comprising these HSCs, methods of using these modified HSCs for treating autoimmune diseases and disorders and for suppressing the immune system. In particular, the engineered modified HSCs or PGE2-stimulated HSCs express the surface marker, programmed cell death-1 ligand 1 (PD-L1).
公开/授权文献
- US20200085878A1 PD-L1 EXPRESSING HEMATOPOIETIC STEM CELLS AND USES 公开/授权日：2020-03-19
信息查询
IPC分类:
